Analysts Set Expectations for GLUE Q4 Earnings

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Stock analysts at Wedbush issued their Q4 2026 earnings estimates for Monte Rosa Therapeutics in a research report issued on Thursday, May 8th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.57) per share for the quarter. Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.81.

GLUE has been the topic of several other research reports. Lifesci Capital initiated coverage on Monte Rosa Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $19.00 price target on the stock. Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday, March 21st.

Monte Rosa Therapeutics Trading Down 2.6%

Shares of NASDAQ GLUE opened at $4.11 on Monday. The company has a market cap of $252.81 million, a price-to-earnings ratio of -2.25 and a beta of 1.52. Monte Rosa Therapeutics has a 12-month low of $3.21 and a 12-month high of $12.40. The stock’s 50 day simple moving average is $5.05 and its 200 day simple moving average is $6.54.

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its stake in Monte Rosa Therapeutics by 7.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company’s stock valued at $49,391,000 after acquiring an additional 515,496 shares in the last quarter. Versant Venture Management LLC bought a new stake in shares of Monte Rosa Therapeutics in the 4th quarter worth $39,231,000. Vanguard Group Inc. raised its stake in shares of Monte Rosa Therapeutics by 24.5% in the 4th quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company’s stock worth $21,905,000 after buying an additional 622,134 shares in the last quarter. BVF Inc. IL bought a new stake in shares of Monte Rosa Therapeutics in the 4th quarter worth $19,185,000. Finally, Marshall Wace LLP raised its stake in shares of Monte Rosa Therapeutics by 187.3% in the 4th quarter. Marshall Wace LLP now owns 499,492 shares of the company’s stock worth $3,466,000 after buying an additional 325,643 shares in the last quarter. Institutional investors own 79.96% of the company’s stock.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Chandra P. Leo bought 10,000 shares of the business’s stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $5.84 per share, with a total value of $58,400.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $58,400. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.90% of the stock is owned by company insiders.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.